21 hours ago
HomeMarket NewsPfizer inks deal with Mylan Pharma to market Ativan and Pacitane in India
Mylan, which has an established presence in the central nervous system therapy segment, is expected to leverage its network and specialist engagement to enhance the reach of these products.
By Sheersh Kapoor February 21, 2025, 2:53:58 PM IST (Published)
Pfizer Ltd has announced a strategic marketing and supply agreement with Mylan Pharmaceuticals Private Limited, aimed at bolstering the distribution and sales of its two well-known brands, Ativan and Pacitane, within India.
The deal, which spans five years, was approved by Pfizer’s Board of Directors following a meeting that concluded on February 21, 2025.
Ativan, primarily used for anxiety disorders, and Pacitane, prescribed for Parkinson’s disease and other neurological conditions, will now be marketed and sold by Mylan under this partnership.
Mylan, which has an established presence in the central nervous system therapy segment, is expected to leverage its network and specialist engagement to enhance the reach of these products.
Pfizer stated that this collaboration would strengthen the in-clinic presence of its products by tapping into Mylan’s expertise in working with neurologists and psychiatrists across India. While the exact financial terms of the agreement remain undisclosed, the company confirmed that commercial arrangements have been mutually agreed upon.
The agreement is limited to the domestic market and does not involve any joint venture or share exchange between the two companies.
Shares of Pfizer Ltd were trading down 0.79% at ₹4,080.15 on the BSE around 2:45 pm.
